A Laboratory Model for Heroin Abuse Medications
opiates
Narcotic-Related Disorders+3
+ Mental Disorders
+ Heroin Dependence
Treatment Study
Summary
Study start date: August 1, 1995
Actual date on which the first participant was enrolled.Abuse of prescription opioid medications has increased dramatically in the U.S. during the past decade, as indicated by a variety of epidemiological sources. However, few studies have systematically examined the relative reinforcing effects of commonly abused opioid medications. The current inpatient study was designed to compare the effects of intravenously delivered fentanyl , oxycodone, morphine, buprenorphine and heroin in morphine-maintained heroin abusers. All of the participants received all of the drugs tested; drugs and doses were administered in non-systematic order.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.8 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 45 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criterion 1. DSM IV criteria for opioid dependence 2. No major mood, psychotic, or anxiety disorder 3. Physically healthy 4. Able to perform study procedures 5. 21-45 years of age 6. Current use of i.v. heroin in amounts/frequencies 7. Not seeking treatment for opioid dependence Exclusion Criterion 1. DSM IV criteria for dependence on drugs other 2. Participants requesting treatment 3. Participants on parole or probation 4. Pregnancy or lactation 5. Birth, miscarriage or abortion with 6 months 6. Recent history of or current significant violent behavior 7. Current major Axis I psychopathology, other than heroin dependence ( e.g., mood disorder with functional impairment or suicide risk, schizophrenia), which might interfere with ability to participate in the study 8. Hepatitis with SGOT or SGPT \> 3 times normal 9. Significant suicide risk 10. Current or history of chronic pain 11. Sensitivity, allergy, or contraindication to opioids
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 2 locations
New York State Psychiatric Institute
New York, United States